Adaptive Biotechnologies Announces New Data Demonstrating the Benefit of Serial MRD Testing with the…
Analysis of the MASTER trial (Abstract 481) showed clonoSEQ’s ability to measure deep and durable responses and permit treatment discontinuation in multiple myeloma patientsData in more than 30 abstracts supports clonoSEQ as a standard of…